PubMed Health⌕ Search

Biomedical subjects

M Schwab

Publications and source records attributed to M Schwab.

At least 19 recordsLinked to original sources
PubMed1992

Plasmid pLTRpoly: a versatile high-efficiency mammalian expression vector.

Plasmid pLTRpoly is an expression vector enabling high-level expression of introduced genes in a variety of cell types. A large multiple cloning site (MCS) and the availability of the full-length nucleotide sequence facilitate the generation of constructs using this vector. Here, constructs made with pLTRpoly have been tested in NIH3T3 mouse fibroblasts.

3T3 Cells↗
PubMed1992

Deletions in the short arm of chromosome 8 are present in up to 90% of human colorectal cancer cell lines.

Cytogenetic analyses of human colon cancer cells have revealed non-random deletions in chromosome arm 8p, among other chromosomal changes. By using 8p-specific DNA probes we could identify allelic loss in 87% of colon cancer cell lines. Corresponding analyses in direct preparations of colon tumor tissues revealed a minimal value of 40% of allelic loss but were obstructed in many instances by contaminating normal tissue. These findings add to the number of non-random genetic alterations occurring during colon carcinogenesis.

Alleles↗
PubMed1992

Identification in human urine of a natural growth inhibitor for cells derived from solid paediatric tumours.

Partially purified urine of healthy human subjects contains several fractions able to inhibit the proliferation of cultured human neuroblastoma cells. One of the most active fractions was further analysed by gas chromatography-mass spectrometry and shown to contain genistein, a substance formed in the human body from precursors obtained by diet. Synthetic genistein was able to inhibit the proliferation of human neuroblastoma cells with a half-maximal effect at 5-10 mumol l-1 concentrations. Genistein displayed similar potencies in inhibiting the proliferation of cells derived from various other solid pediatric tumours. Our results suggest that genistein is a natural antineoplastic agent present in diet and that it could be useful for the therapy of paediatric tumours.

Cell Division↗
PubMed1992

Multiple amplicons of discrete sizes encompassing N-myc in neuroblastoma cells evolve through differential recombination from a large precursor DNA.

Human neuroblastoma cells often carry cytogenetic abnormalities signaling amplification of the gene N-myc. In most cell lines amplified N-myc is localized in homogeneously staining regions (HSRs). Varying proportions of the amplified DNA consist of multiple tandem arrays of DNA segments encompassing N-myc. Here we report the cloning and sequencing of a DNA breakpoint which represents the joint of the tandem repeats of a 280-kb amplicon of neuroblastoma line NMB. The breakpoint is located in the first intron of the N-myc gene and leads to the deletion of the 5' region of N-myc in this 20-copy amplicon. The representation of DNA derived from the non-N-myc part of the novel joint in the different amplicons suggests that an increase in N-myc copy numbers involves a multistep process proceeding from large 'precursors' to smaller multicopy amplicons.

Base Sequence↗
PubMed1992

Deletion mapping of chromosomes 14q and 1p in human neuroblastoma.

It has been suggested that loss of heterozygosity (LOH) on the short arm of chromosome 1 is a critical event for the development of neuroblastoma, and we have previously shown frequent LOH on chromosome 14 in neuroblastoma. To pursue these observations, especially to define further the regions which are commonly deleted in the tumor, we examined for allelic losses in 27 cases of neuroblastomas by using a number of polymorphic DNA markers for chromosomes 14q and 1p. LOH was observed in 10 out of the 25 informative cases (40%) on chromosome 14q and in eight out of the 21 informative cases (38%) on 1p. The commonly deleted regions were distal to the D14S13 locus (14q32-qter) on chromosome 14 and distal to the D1S112 locus (1p36.1-pter) on chromosome 1. These results strongly suggest that tumor-suppressor genes important in the pathogenesis of human neuroblastoma are located on the distal part of both chromosomes 14q and 1p.

Alleles↗
PubMed1991

The N-Myc oncoprotein is associated in vivo with the phosphoprotein Max(p20/22) in human neuroblastoma cells.

Proteins encoded by the proto-oncogenes c-myc, L-myc, and N-myc contain at their carboxy-terminus a tripartite segment comprising a basic DNA binding region (BR), a helix-loop-helix (HLH) and a leucine zipper motif (Zip), that are believed to be involved in DNA binding and protein-protein interaction. The N-Myc oncoprotein is overexpressed in certain human tumors that share neuroectodermal features due to amplification of the N-myc gene. Using a monoclonal antibody directed against an N-terminal epitope of the N-Myc protein in immunoprecipitations performed with extracts of neuroblastoma cells, two nuclear phosphoprotein, p20/22, forming a hetero-oligomeric complex with N-Myc are identified. Both proteins are phosphorylated by casein kinase II in vitro. By partial proteolytic maps we show that p20 and p22 are structurally related to each other and that p20 is identical with Max, a recently described in vitro binding partner of myc proteins. Time course experiments show the presence of the complex in cellular extracts immunoprecipitated within a 5 min interval after the preparation of the cell extract. While the expression of N-myc is restricted, expression of both Max(p20/22) and the murine homolog Myn(p20/22) was observed in cells of diverse human and murine embryonal lineages as detected by heterologous complex formation. By introduction of expression vectors containing the wild type N-myc gene or N-myc genes with in frame deletions or point mutations into recipient cells and subsequent immunoprecipitation of the resulting N-Myc proteins we show that the HLH-Zip region is essential to the formation of the N-Myc-p20/22 complex.

Animals↗
PubMed1991

Enhanced expression of the cellular oncogene MYCN and progression of human neuroblastoma.

A central issue in cancer research is how tumors evolve and acquire a more aggressive phenotype. It is a widely discussed hypothesis that tumor cell populations progress by evolutionary change as a result of the generation of a variant cell through genomic instability followed by selection of particular variant clones having a growth advantage within the particular tissue environment. Genetic instability appears to be characteristic of neoplastic cells, but no consistent increase in instability seems to accompany progression of the malignant phenotype of the tumor. It is reasonable to assume that quantitative or qualitative changes of cellular oncogenes contribute to the emergence of more malignant phenotypes. Although any one of the molecular changes of cellular oncogenes identified over the past years is a good candidate as an element in progression, amplification appears particularly frequently as a correlate to advanced tumor stage. The fact that amplification does not show up in all progressing tumors of a particular type, for instance in only 50% of advanced-stage neuroblastomas, is often construed as speaking against a role in progression. One should be aware, however, that it is the enhanced expression of a gene consequent to amplification and not amplification per se that affects the cellular phenotype. There are alternative molecular pathways by which expression of a particular gene may become deregulated. During the past decade much information has accrued about genetic alterations in tumor cells. The activation of the oncogenic potential of cellular genes can take different routes among which mutational alteration, translocation and amplification predominate. In particular, amplification has found its way to practical use due to its association with more aggressively growing types of human cancer. MYCN amplification in neuroblastoma is a paradigm for the prognostic significance of oncogene alteration, and at the same time has represented the clinical debut of oncogene research. The full significance of oncogene amplification as a predictor for poor prognosis became clear with the more recent identification of amplified ERBB2 in aggressively growing breast cancers. The state of the art is that amplified cellular oncogenes define cancer patients who have a poor prognosis and require a specific therapeutic regimen.

Chromosome Aberrations↗
PubMed1991

The TraM protein of plasmid R1 is a DNA-binding protein.

The TraM protein of the resistance plasmid R1 was purified to homogeneity and used for DNA-binding studies. Both gel retardation- and footprint experiments showed that TraM specifically binds to DNA of plasmid R1 comprising the region between the origin of transfer and the traM gene. Several TraM molecules bind and, according to the footprint experiments, two distinct sites of specific binding exist. The two sites are separated from each other by 12 nucleotides and each contains an inverted repeat. DNase I protection assays showed that the initial TraM binding occurs at these palindromic sequences. At higher protein concentrations the lengths of the DNA segments protected by TraM were increased towards the traM gene. In one region this extension leads to binding of TraM protein at its own promoters.

Bacterial Proteins↗
PubMed1991

Self-reported exertion levels on time/activity diaries: application to exposure assessment.

Recent developments in air pollution analysis have focused on methods for collecting data on contaminant levels in the locations actually frequented by people, especially personal monitoring. While there is still much to understand about human exposures, the next advancements will be in the area of dose assessment. This paper discusses the results of a study designed to provide data for linking exposure to dose. Specifically, we used time/activity diaries to collect information on the exertion levels associated with the reported activities. As part of a community health study, 91 children between the ages of 9 and 11 kept diaries over a two-week summer-time period (July 1989) and during a two-week school-time period (September 1989). The diary was also administered for two days to 42 teenagers between the ages of 15 and 17. This paper describes our concerns about interpreting self-reported exertion levels, particularly with respect to the disparity between participant and researcher perception and coding. We then present the distribution of exertion levels associated with children's activities, highlighting seasonal, day-of-week, and age-group differences.

Adolescent↗
PubMed1991

The MYCN protein of human neuroblastoma cells is phosphorylated by casein kinase II in the central region and at serine 367.

The MYCN gene has been implicated in certain neuronal tumours, such as neuroblastomas and retinoblastomas. These tumours express high levels of mRNA and protein of MYCN as a result of amplification. MYCN encodes a short-lived nuclear phosphoprotein whose function has not yet been elucidated. This study was undertaken to determine the pattern of MYCN protein (pMYCN) phosphorylation in human neuroblastoma cells. We report that pMYCN is phosphorylated in vitro by purified casein kinase II (CK-II). Two-dimensional phosphopeptide maps showed that most of the phosphopeptides of pMYCN phosphorylated in vitro by CK-II correspond to those phosphorylated in vivo. Fine mapping of the phosphorylation sites was performed using two synthetic MYCN peptides corresponding to pMYCN CK-II consensus sequences. Both peptides were found to be phosphorylated by CK-II and competitively inhibited CK-II phosphorylation of pMYCN in vitro. Thus, we have localized two major CK-II phosphorylation sites in pMYCN, one to the highly acidic central region and the second to serine 367 proximal to the C-terminus. Our data demonstrate that pMYCN is a physiological substrate for CK-II and, since CK-II activity is stimulated in response to mitogens, CK-II phosphorylation of pMYCN may, therefore, represent one signal transduction pathway used by neuroblastoma cells.

Amino Acid Sequence↗
PubMed1991

Localization of regulatory elements controlling human MYCN expression.

Expression of the cellular oncogene MYCN is restricted to few cell lineages and is highest during development both in mouse and in humans. In pursuit of elucidating the mechanisms underlying MYCN regulation we introduced a human MYCN clone (pNb-9) with approximately 2.5 kbp 5'- and 6 kbp 3'-flanking genomic sequences into different murine and human cell lines as well as into mice. In all cases we found a correlation between the expression of the exogenous and the endogenous MYCN. Among cell lines, only those expressing the endogenous gene also expressed the transfected gene. In the transgenic mice transcripts of the transgene were present in proportion to the transcripts of the endogenous MYCN gene with the highest level in the brain. Therefore, the genetic information necessary for regulated expression of MYCN appears to be contained in pNb-9. To localize the DNA-regions responsible for regulated expression, we generated MYCN/CAT hybrid genes with different portions of the putative MYCN promoter region linked to the reporter gene. Transient transfections into various murine and human cell lines identified three DNA regions apparently involved in the regulation of expression. One region about 200 bp upstream of the transcriptional start site is responsible for a basal level of MYCN expression. A second region located about 800 bp further upstream appears to be involved in cell type-specific gene activation. The third regulatory element is located at the 3' end of the first exon and/or in the first intron and may mediate tissue-specific down regulation of gene expression.

Animals↗
PubMed1990

Human colorectal cancer: high frequency of deletions at chromosome 1p35.

Cytogenetic analyses of human colon cancer cells have revealed a high frequency of chromosome 1p deletions among other chromosomal abnormalities. In order to find out whether these chromosomal alterations are manifestations of loss of genetic material, we surveyed DNA of 62 primary tumors, 7 metastases, and matching peripheral blood cells with a panel of polymorphic DNA probes that detect different loci on chromosome 1p. A portion of the probes was derived from a microclone bank generated by microdissection and microcloning of 1p35----pter DNA. In 42% of the colon carcinomas allelic loss was observed with at least one probe. The deletions were of different sizes but always included a region involving band 1p35, except for two tumors in which allelic loss was detected more proximally. The frequency of 1p deletion in the metastases was higher than in the primary tumors. These data indicate that genetic information related to tumorigenesis is located within or nearby region 1p35 and that deletion of this region occurs later in tumor development. Our results add to the number of genetic changes presumably involved in colon cancerogenesis.

Alleles↗
PubMed1990

Reduction of N-myc expression by antisense RNA is amplified by interferon: possible involvement of the 2-5A system.

Expression of myc-box genes can be reduced by Interferon (c-myc in Daudi cells) or Retinoic acid (N-myc in neuroblastoma cells). Interferon did not reduce N-myc expression in neuroblastoma cells. However, after transfection of the human neuroblastoma cell line LS with a vector, providing the Cadmium inducible expression of an antisense N-myc transcript, drastic reduction of N-myc RNA was achieved in these cells by incubation with Cadmium and Interferon. Treatment with Cadmium alone resulted in a comparably small reduction of N-myc transcripts in these cells. Interferon alone did not appreciably affect N-myc expression. Reduction of N-myc was accompanied with reduced cell proliferation and morphological differentiation. It is assumed that most of the inhibitory effects observed are mediated by the Interferon inducible 2-5A system.

2',5'-Oligoadenylate Synthetase↗